![]() | Up a level |
Munir, Talha, Cairns, David A, Bloor, Adrian, Allsup, David, Cwynarski, Kate, Pettitt, Andrew ORCID: 0000-0002-0907-8950, Paneesha, Shankara, Fox, Christopher P, Eyre, Toby A, Forconi, Francesco
ORCID: 0000-0002-2211-1831 et al (show 23 more authors)
(2024)
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
The New England journal of medicine, 390 (4).
pp. 326-337.
Sharman, Jeff P, Coutre, Steven E, Furman, Richard R, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian W et al (show 14 more authors)
(2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Journal of Clinical Oncology, 37 (16).
pp. 1391-1402.
Lin, Wei-Yu, Fordham, Sarah E, Sunter, Nicola, Elstob, Claire, Rahman, Thahira, Willmore, Elaine, Shepherd, Colin, Strathdee, Gordon, Mainou-Fowler, Tryfonia, Piddock, Rachel et al (show 26 more authors)
(2021)
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.
NATURE COMMUNICATIONS, 12 (1).
665-.
Rose-Zerilli, Matthew John Jerome, Parker, Helen, Larrayoz, Marta, Clifford, Ruth, Blakemore, Stuart, Edelmann, Jennifer, Gibson, Jane, Wang, Jun, Ljungstrom, Viktor, Chaplin, Tracy et al (show 26 more authors)
(2015)
Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia.
, England.
Schuh, Anna H, Parry-Jones, Nilima, Appleby, Niamh, Bloor, Adrian, Dearden, Claire E, Fegan, Christopher, Follows, George, Fox, Christopher P, Iyengar, Sunil, Kennedy, Ben et al (show 7 more authors)
(2018)
Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.
BRITISH JOURNAL OF HAEMATOLOGY, 182 (3).
pp. 344-359.
Hillmen, Peter, Rawstron, Andy C, Brock, Kristian, Muñoz-Vicente, Samuel, Yates, Francesca J, Bishop, Rebecca, Boucher, Rebecca, MacDonald, Donald, Fegan, Christopher, McCaig, Alison et al (show 9 more authors)
(2019)
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Journal of Clinical Oncology, 37 (30).
pp. 2722-2730.
Ghia, Paolo, Coutre, Steven E, Cheson, Bruce D, Barrientos, Jacqueline C, Hillmen, Peter, Pettitt, Andrew R, Zelenetz, Andrew D, Shreay, Sanatan, Hallek, Michael and Furman, Richard R
(2020)
Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial.
HAEMATOLOGICA, 105 (10).
E519-E522.
Linley, Adam J ORCID: 0000-0002-8176-5560, Karydis, Laura I, Mondru, Anil K, D'Avola, Annalisa, Al Shmrany, Humood, Cicconi, Silvia, Griffin, Rebecca, Forconi, Francesco, Pettitt, Andrew R, Kalakonda, Nagesh
ORCID: 0000-0002-5300-1360 et al (show 7 more authors)
(2021)
Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells.
CLINICAL CANCER RESEARCH, 27 (20).
pp. 5647-5659.
Pettitt, Andrew R, Jackson, Richard, Cicconi, Silvia ORCID: 0000-0001-5507-6203, Polydoros, Fotis, Yap, Christina, Dodd, James, Bickerstaff, Matthew, Stackpoole, Michael, Khan, Umair T
ORCID: 0000-0002-9470-3481, Carruthers, Stacey et al (show 16 more authors)
(2020)
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial.
HAEMATOLOGICA, 105 (12).
pp. 2868-2871.
Eagle, Gina, Zhuang, Jack ORCID: 0000-0003-3245-0789, Oates, Melanie, Kitteringham, Neil, Herbert, John, Falciani, Francesco
ORCID: 0000-0003-1432-2871, Pettitt, Andrew, Park, Kevin, Jenkins, Rosalind, Devereux, Stephen et al (show 2 more authors)
(2017)
Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples.
.
Robbe, Pauline, Ridout, Kate E, Vavoulis, Dimitrios V, Dreau, Helene, Kinnersley, Ben, Denny, Nicholas, Chubb, Daniel, Appleby, Niamh, Cutts, Anthony, Cornish, Alex J et al (show 33 more authors)
(2022)
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features.
NATURE GENETICS, 54 (11).
1675-+.
Offner, Fritz, Robak, Tadeusz, Janssens, Ann, Babu, K Govind, Kloczko, Janusz, Grosicki, Sebastian, Mayer, Jiri, Panagiotidis, Panagiotis, Schuh, Anna, Pettitt, Andrew et al (show 5 more authors)
(2020)
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
BRITISH JOURNAL OF HAEMATOLOGY, 190 (5).
pp. 736-740.
Kreuzer, Karl-Anton, Furman, Richard R, Stilgenbauer, Stephan, Dubowy, Ronald L, Kim, Yeonhee, Munugalavadla, Veerendra, Lilienweiss, Esther, Reinhardt, Hans Christian, Cramer, Paula, Eichhorst, Barbara et al (show 4 more authors)
(2020)
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
Leukemia, 34 (1).
pp. 296-300.
Alharthi, Afaf, Beck, Daniel, Howard, Dena R, Hillmen, Peter, Oates, Melanie, Pettitt, Andrew and Wagner, Simon D ORCID: 0000-0002-8914-0370
(2018)
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.
BMC research notes, 11 (1).
280-.
Pratt, Guy, Yap, Christina, Oldreive, Ceri, Slade, Daniel, Bishop, Rebecca, Griffiths, Mike, Dyer, Martin JS, Fegan, Chris, Oscier, David, Pettitt, Andrew et al (show 9 more authors)
(2018)
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY, 182 (3).
pp. 429-433.